-
BioMarin’s Voxzogo shows promise in hypochondroplasia
12 Apr 2024 14:32 GMT
BioMarin’s Voxzogo has been shown … in children with hypochondroplasia, a genetic cause of very short stature … phase 2 trial, funded by BioMarin, but led by investigators at … ,000 to 40,000 births.
BioMarin has said that expanding the …
-
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
10 Apr 2024 13:38 GMT
… BioMarin is a global biotechnology Company dedicated to transforming lives through genetic … cause of the genetic conditions. BioMarin's …
Traci McCarty
Marni Kottle
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
(415) 455 …
-
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
12 Mar 2024 17:26 GMT
… the root cause of the genetic conditions. BioMarin's unparalleled research … -genomics-acmg-annual-clinical-genetics-meeting-302085829.html
SOURCE BioMarin Pharmaceutical Inc.
-
BioMarin Subpoena Potentially Signals Continued Investigations into Sponsored Testing Programs
08 Mar 2024 22:08 GMT
… February 26, 2024, BioMarin Pharmaceutical, Inc. (“BioMarin”) disclosed in its annual … , manufacturers, laboratories and genetic counseling entities who participate in … 47;publications/sponsored-genetic-testing-programs-compliance-considerations- …
-
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
07 Mar 2024 15:27 GMT
… BioMarin is a global biotechnology company dedicated to transforming lives through genetic … root cause of genetic conditions. BioMarin's unparalleled …
Marni Kottle
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
(415) 455 …
-
BioMarin Scheduled to Participate in March Investor Conferences
01 Mar 2024 14:15 GMT
… BioMarin is a global biotechnology Company dedicated to transforming lives through genetic … root cause of the genetic conditions. BioMarin's unparalleled research …
Traci McCarty
Marni Kottle
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
(415) …
-
BioMarin testing programs for 2 top-selling drugs under scrutiny from DOJ
28 Feb 2024 13:04 GMT
… medicines are for the rare genetic condition mucopolysaccharidosis, a lysosomal … Vimizim and Naglazyme,” a BioMarin spokesperson said in an emailed … news made little impact on BioMarin's shares as … for drugs that are among BioMarin’s best sellers. Vimizim …
-
DOJ subpoenas BioMarin over sponsored testing program for rare disease drugs
27 Feb 2024 19:58 GMT
… has issued a subpoena to BioMarin over issues with its sponsored … .
The subpoena seeks documents on BioMarin’s sponsored testing programs for … replacement therapy for the rare genetic disease Morquio A syndrome that …
-
BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies
27 Feb 2024 12:32 GMT
Bengaluru: BioMarin Pharmaceutical has received a … its therapies Vimizim and Naglazyme, BioMarin said.
"We have produced … said in the filing.
BioMarin said the subpoena was not … a rare genetic disorder that affects major organ systems.
BioMarin's …
-
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2023 Earnings Call Transcript
23 Feb 2024 17:59 GMT
… about the business prospects of BioMarin Pharmaceutical, Inc., including expectations … idiopathic short stature and multiple genetic short stature pathway conditions, … May. BioMarin is securing our leadership position for treating multiple genetic central …